HK1257100A1 - 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法 - Google Patents

使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法

Info

Publication number
HK1257100A1
HK1257100A1 HK18116351.9A HK18116351A HK1257100A1 HK 1257100 A1 HK1257100 A1 HK 1257100A1 HK 18116351 A HK18116351 A HK 18116351A HK 1257100 A1 HK1257100 A1 HK 1257100A1
Authority
HK
Hong Kong
Prior art keywords
composition
methods
organic compounds
small organic
protein activity
Prior art date
Application number
HK18116351.9A
Other languages
English (en)
Inventor
Thomas E Barta
Jonathan William Bourne
Kyle D Monroe
Michael M Muehlemann
Anjali Pandey
Simeon Bowers
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of HK1257100A1 publication Critical patent/HK1257100A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK18116351.9A 2015-08-21 2018-12-20 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法 HK1257100A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208054P 2015-08-21 2015-08-21
US201662298852P 2016-02-23 2016-02-23
PCT/US2016/047810 WO2017034994A1 (en) 2015-08-21 2016-08-19 Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity

Publications (1)

Publication Number Publication Date
HK1257100A1 true HK1257100A1 (zh) 2019-10-11

Family

ID=58101008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116351.9A HK1257100A1 (zh) 2015-08-21 2018-12-20 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法

Country Status (4)

Country Link
US (2) US10821106B2 (zh)
EP (1) EP3337497B1 (zh)
HK (1) HK1257100A1 (zh)
WO (1) WO2017034994A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3337497B1 (en) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
WO2017034997A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
CN105214087B (zh) 2015-10-29 2017-12-26 陈敏 Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US769101A (en) * 1903-12-30 1904-08-30 Melvin Mitchell Attachment for grain-drills.
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
JP2969359B2 (ja) 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
MX9100517A (es) 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
ES2157204T3 (es) 1991-04-17 2001-08-16 Upjohn Co Derivados de (s)-3-fenilpiperidina sustituidos, su preparacion y uso como antagonistas de autorreceptores de dopamina.
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
EP0707490A1 (en) * 1993-06-18 1996-04-24 University Of Cincinnati Neuropeptide y antagonists and agonists
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
CA2187257A1 (en) 1995-10-12 1997-04-13 Enrique Luis Michelotti Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NZ501258A (en) 1997-07-11 2001-07-27 Smithkline Beecham P Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression
US6381025B1 (en) 1999-08-19 2002-04-30 Texas Tech University Interferometric detection system and method
WO2001096301A1 (fr) 2000-06-14 2001-12-20 Toray Industries, Inc. Procedes de production de derive de piperidine racemique et de production de derive de piperidine a activite optique
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
MXPA04008104A (es) 2002-02-22 2006-05-25 Upjohn Co Derivados de arilsulfona.
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2003274551A1 (en) 2002-11-12 2004-06-03 Pfizer Products Inc. Quinoline derivatives
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
TW200505450A (en) 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AU2005247405A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
EP1909791A1 (en) 2005-06-30 2008-04-16 Prosidion Limited G-protein coupled receptor agonists
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US7750012B2 (en) 2005-12-21 2010-07-06 Decode Genetics Ehf Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
WO2007097289A1 (ja) 2006-02-20 2007-08-30 Takeda Pharmaceutical Company Limited 新規医薬
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8445217B2 (en) 2007-09-20 2013-05-21 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
EP2223037A4 (en) 2007-12-10 2016-08-03 Molecular Sensing Inc INTERFEROMETER AT STABLE TEMPERATURE
US8673850B2 (en) * 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
CN102596941A (zh) 2009-10-01 2012-07-18 卡迪拉保健有限公司 用于治疗血脂异常和相关疾病的化合物
WO2012039660A1 (en) 2010-09-20 2012-03-29 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN105693645B (zh) 2011-05-10 2018-10-09 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
US20150057949A1 (en) 2012-04-19 2015-02-26 Molecular Sensing, Inc. Event Detection For Back-Scattering Interferometry
JP2015517579A (ja) 2012-05-25 2015-06-22 カタバシス ファーマシューティカルズ，インコーポレイテッド プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）を低下させる方法
EP2864309A1 (en) 2012-06-25 2015-04-29 Cadila Healthcare Limited Compounds for the treatment of dyslipidemia and other diseases
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US10287317B2 (en) 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
JP2016508722A (ja) 2013-02-15 2016-03-24 エスアールエックス カーディオ，エル エル シー 血清低密度リポタンパク質（ｌｄｌ）レベルを調節するためのｐｃｓｋ９（プロタンパク質転換酵素サブチリシン／ケキシン９型）アロステリック結合リガンド
ES2489815B1 (es) 2013-02-21 2015-08-10 Centro De Investigación Príncipe Felipe Nuevos p-terfenilos hexakis-sustituidos con grupos bilaterales para el tratamiento de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) y otras enfermedades
US20160039945A1 (en) * 2013-03-15 2016-02-11 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
WO2014150395A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
WO2015024016A2 (en) 2013-08-16 2015-02-19 Duke University 2-piperidinyl substituted n,3-dihydroxybutanamides
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016029037A1 (en) 2014-08-21 2016-02-25 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
US20170267689A1 (en) 2014-08-25 2017-09-21 The Governors Of The University Of Alberta Stimuli-switchable moieties, monomers and polymers incorporating stimuli-switchable moieties, and methods of making and using same
CN105753817A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 一类取代氮杂环衍生物及其应用
WO2016107603A1 (zh) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
WO2017034997A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
EP3337497B1 (en) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CN109715167A (zh) * 2016-08-03 2019-05-03 神经孔疗法股份有限公司 脂质取代的氨基1,2-和1,3-二醇化合物作为tlr2二聚化的调节剂
US11091466B2 (en) 2017-03-17 2021-08-17 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of PCSK9
CA3142890A1 (en) 2019-06-14 2020-12-17 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)
US20220193058A1 (en) 2020-12-16 2022-06-23 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)

Also Published As

Publication number Publication date
EP3337497A1 (en) 2018-06-27
WO2017034994A1 (en) 2017-03-02
EP3337497B1 (en) 2023-07-12
US20210236481A1 (en) 2021-08-05
EP3337497A4 (en) 2019-04-17
US10821106B2 (en) 2020-11-03
US11944619B2 (en) 2024-04-02
US20180237381A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
HK1257100A1 (zh) 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法
IL267090A (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them
EP3080100A4 (en) Inhibitors of lysine specific demethylase-1
HK1211471A1 (zh) 通過抑制含布羅莫結構域蛋白 治療 介導的疾病
CL2015000261A1 (es) Alimento para peces de piscifactoría y método para promover el crecimiento de peces de piscifactoría usando el mismo.
EP3558303A4 (en) AMINO ACID COMPOUNDS AND METHOD FOR USE
HK1213471A1 (zh) 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
HK1222864A1 (zh) 的小分子調節劑和其使用方法
EP3407916A4 (en) PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE THE CELLULAR RETENTION OF COMPOUNDS
ZA201701844B (en) Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)
EP3142652A4 (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
EP2968244A4 (en) COMPOSITIONS AND METHODS FOR USING ALIGAL COMPOUNDS
HK1260897A1 (zh) 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法
EP3313865A4 (en) SYNTHETIC PEPTIDE COMPOUNDS AND METHODS OF USE
EP3228626A4 (en) Peptide having activity to improve skin condition and use thereof
EP3092244A4 (en) Dipeptides as inhibitors of human immunoproteasomes
EP3219324A4 (en) Application of dipeptide as ace enzyme activity inhibitor
EP3191116A4 (en) METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USE OF SAME TO MODULATE mTORC1
EP3198038A4 (en) Compositions and methods to modulate cell activity
IL248567A0 (en) Using compounds known as d-amino acid oxidase inhibitors
EP3445170A4 (en) CHINOLINE COMPOUNDS AS RAGE ACTIVITY MODULATORS AND USES THEREOF
EP3193904A4 (en) Dipeptidomimetics as inhibitors of human immunoproteasomes
EP3036219A4 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
EP2994461A4 (en) Methods of treating skin conditions using cyclolignan compounds
EP2976130A4 (en) STRUCTURING OF A COSMETIC COMPOSITION USING ORGANOGELES